The Open Colorectal Cancer Journal

2010, 3 : 23-26
Published online 2010 April 21. DOI: 10.2174/1876820201003010023
Publisher ID: TOCOLCJ-3-23

Bevacizumab May Overcome Clinical Tumor Drug Resistance to Irinotecan Based Chemotherapy in Patients with Metastatic Colorectal Cancer: Case Report

J.M. Zekri and M.Z. Abubacker
Department of Oncology, King Faisal Specialist Hospital and Research Centre, P.O. BOX 40047, Jeddah 21499, MBC#: J-64, Kingdom of Saudi.

ABSTRACT

Introduction: In the management of patients with metastatic colorectal cancer (mCRC) failing anti-cancer agents/regimens are substituted by others. There is no data in the literature showing that combining 2 failing agents/regimens can induce tumor response.

Case: We report a case with mCRC who failed first line XELOX/bevacicumab and second line FOLFIRI. However, the tumour responded to third line FOLFIRI/bevacizumab.

Conclusion: Retreatment with bevacizumab in combination with a failing chemotherapy regimen is a possible treatment option after exhaustion of all standard treatments. This approach seems to be effective in overcoming clinical tumor drug resistance to irinotecan based chemotherapy.